Athena Diagnostics® is pleased to announce that on March 27, 2013 we will begin offering expanded testing services for Charcot-Marie-Tooth (CMT) disease. The new testing will be performed in a reflexive manner; testing for the most common cause of CMT first (PMP22 duplication/deletion testing) followed by sequencing of the genes associated with your patient’s specific phenotype. To simplify the ordering process, the new testing approach will leverage published Practice Parameters by the American Academy of Neurology. For your ordering convenience, a testing algorithm is shown on the reverse side of this update.
Additionally, as part of this launch, the current tests will be replaced and no longer orderable. Please update your systems accordingly in anticipation of this new testing.
References: 1. http://www.neurology.org/content/72/2/185.full.pdf+html.